Irosin 5 Injection contains Iron Sucrose at a concentration of 20 mg/ml and is indicated for the treatment of iron deficiency anemia, particularly in patients with chronic kidney disease (CKD) undergoing hemodialysis or those who are intolerant to or inadequately responsive to oral iron therapy. Iron Sucrose is an intravenous iron preparation that replenishes iron stores by delivering bioavailable iron directly into the bloodstream, facilitating hemoglobin synthesis and erythropoiesis. The formulation is designed to minimize the risk of adverse reactions commonly associated with older iron complexes, offering a favorable safety profile when administered under proper medical supervision. Irosin 5 Injection should be administered intravenously, with dosage and frequency tailored according to the patient’s iron requirements, hemoglobin levels, and clinical condition. It is essential to monitor serum ferritin and transferrin saturation to avoid iron overload. Contraindications include known hypersensitivity to Iron Sucrose or any component of the formulation, and active systemic infections. Caution is advised in patients with a history of anaphylaxis to intravenous iron products. Adverse effects may include mild hypotension, nausea, dizziness, and injection site reactions. Irosin 5 Injection is a critical therapeutic agent in managing iron deficiency anemia when oral supplementation is ineffective or contraindicated.